title: What is the future for drug development in atherosclerosis and dyslipidaemia?
abstract: Major companies have recently announced a reduction or termination of their work in cardiovascular disease, specifically atherosclerosis and dyslipidaemia. This editorial considers the background to these developments, relating it to the continuing development of the lipoprotein-associated phospholipase A2 inhibitor darapladib and the potential for the field in the future.
authors.affiliation: 291 Knightsfield, Welwyn Garden City, Herts AL8 7NH, UK +44 1707 330022 ; +44 1707 330022 ; keith@suckling291.freeserve.co.uk.
authors.forename: Keith
authors.initials: K
authors.lastname: Suckling